Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1-c]benzodiazepines. 1994

P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Italy.

A new class of pyrrolo[1,4]benzodiazepine (PBD) analogues featuring a pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone ring system has been designed and synthesized. These compounds, 2a-o, are characterized by the substitution of the aromatic A ring, characteristic of the PBDs, with a disubstituted pyrazole ring bearing alkyl and benzyl substituents at N6 or N7 and alkyl or carbomethoxy substituents at C8. Biological evaluation revealed an appreciable in vitro cytotoxic activity for compounds 2a,b,f-i.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001570 Benzodiazepinones
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
December 2002, Journal of enzyme inhibition and medicinal chemistry,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
February 2018, Heliyon,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
April 2011, Chemical reviews,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
February 2009, Bioorganic & medicinal chemistry,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
February 2014, Combinatorial chemistry & high throughput screening,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
January 1992, Tetrahedron,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
June 1986, Journal of medicinal chemistry,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
September 2010, European journal of medicinal chemistry,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
August 2002, Bioorganic & medicinal chemistry letters,
P G Baraldi, and A Leoni, and B Cacciari, and S Manfredini, and D Simoni, and M Bergomi, and E Menta, and S Spinelli
March 2005, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!